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Primary brain tumors are composed of tumor cells, neural/glial tissues, edema, and vascula-
ture tissue. Conventional MRI has a limited ability to evaluate heterogeneous tumor patholo-
gies. We developed a novel diffusion MRI-based method—Heterogeneity Diffusion Imaging
(HDI)—to simultaneously detect and characterize multiple tumor pathologies and capillary
blood perfusion using a single diffusion MRI scan.
Methods
Seven adult patients with primary brain tumors underwent standard-of-care MRI protocols
and HDI protocol before planned surgical resection and/or stereotactic biopsy. Twelve
tumor sampling sites were identified using a neuronavigational system and recorded for
imaging data quantification. Metrics from both protocols were compared between World
Health Organization (WHO) II and III tumor groups. Cerebral blood volume (CBV) derived
from dynamic susceptibility contrast (DSC) perfusion imaging was also compared with the
HDI-derived perfusion fraction.
Results
The conventional apparent diffusion coefficient did not identify differences between WHO II
and III tumor groups. HDI-derived slow hindered diffusion fraction was significantly elevated
in the WHO III group as compared with the WHO II group. There was a non-significantly
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increasing trend of HDI-derived tumor cellularity fraction in the WHO III group, and both
HDI-derived perfusion fraction and DSC-derived CBV were found to be significantly higher
in the WHO III group. Both HDI-derived perfusion fraction and slow hindered diffusion frac-
tion strongly correlated with DSC-derived CBV. Neither HDI-derived cellularity fraction nor
HDI-derived fast hindered diffusion fraction correlated with DSC-derived CBV.
Conclusions
Conventional apparent diffusion coefficient, which measures averaged pathology properties
of brain tumors, has compromised accuracy and specificity. HDI holds great promise to
accurately separate and quantify the tumor cell fraction, the tumor cell packing density,
edema, and capillary blood perfusion, thereby leading to an improved microenvironment
characterization of primary brain tumors. Larger studies will further establish HDI’s clinical
value and use for facilitating biopsy planning, treatment evaluation, and noninvasive tumor
grading.
Introduction
Gliomas account for the majority of primary brain tumors in adults; they represent 26.5% of
primary brain tumors and 80.7% of malignant brain tumors [1]. Typically, malignant gliomas
contain heterogeneous pathologies that reflect regional diversity in tumor cell proliferation
[2], immune infiltration, tumor vessel density, necrosis, and cystic degeneration. This hetero-
geneity makes clinical diagnosis and management very challenging.
Current standard-of-care imaging for newly diagnosed patients with brain tumors includes
anatomical magnetic resonance imaging (MRI) with and without contrast to identify general
characteristic features of the tumor, including its location, size, and extent. However, anatomi-
cal MRI techniques alone are limited for the evaluation of tumor heterogeneity, especially in
tumors that demonstrate little or no enhancement. Advanced MRI techniques such as diffu-
sion MRI [3, 4], MR spectroscopy [5, 6] and MR perfusion [7] provide more pathophysiologic
information, and they have demonstrated the potential to characterize tumor types and to dif-
ferentiate recurrent tumor from pseudo progression. Among these advanced techniques, diffu-
sion MRI holds a unique position due to its sensitivity when probing the microenvironment of
biological tissues at a cellular level. Clinically, apparent diffusion coefficient (ADC) maps have
been used to grade primary brain tumors [8, 9], to define tumor cellularity [10], and to assess
brain tumor response to therapy [11, 12]. However, conventional ADC measures average the
diffusivity of multiple pathologies coexisting within each tumor voxel, which significantly lim-
its the accuracy and specificity of this method for characterizing neoplastic pathologies.
Perfusion MRI provides important diagnostic information about microvascularity within
brain tumors, and it can be used to differentiate tumor types and tumor grades [7, 13]. Quanti-
tative and physiologic information provided by diffusion and perfusion MRI are complimen-
tary, and the integration of these two techniques could significantly improve diagnostic
confidence [14]. However, imaging properties examined by different imaging techniques may
suffer mislocalization [15], which could increase registration errors and decrease diagnostic
accuracy. The accurate and simultaneous imaging and quantification of tumor pathological
heterogeneity and vascularity—in one session—will be highly favored to reduce registration
error, thereby improving clinical diagnosis, treatment, and management.
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In this article, we present and examine a novel diffusion MRI technique called Heterogene-
ity Diffusion Imaging (HDI), which is capable of characterizing heterogeneous tumor composi-
tion and microvascularity simultaneously from a single clinical diffusion MRI scan. HDI
employs a multiple diffusion compartment model, which was developed based on diffusion
basis spectrum imaging (DBSI) [16, 17]. By modeling the confounding effects of anatomical
complexities and neuropathologies, this approach is able to disentangle the heterogeneous
pathological components that are mixed in one imaging voxel [16–20]. In the current study,
HDI was employed to quantify tumor cellularity, slow versus fast hindered diffusion fraction,
and perfusion effect in each tumor voxel. We hypothesized that HDI would be more sensitive




This prospective single-center pilot study was approved by the Washington University in
St. Louis Institutional Review Board. Seven adults with primary brain tumors were recruited
from the Washington University School of Medicine between 2015 and 2016. They underwent
the standard-of-care imaging protocol and HDI diffusion MRI before planned standard-of-
care surgical resection and/or stereotactic biopsy. The study was carried out in accordance
with the guidelines of the institutional review board of the Washington University Human
Research Protection Office. Written informed consent was obtained from all participants. The
age range, patient tumor type, and tumor grade are summarized in Table 1. There were four
female and three male subjects in this study. Areas of tumor sampling were identified intrao-
peratively using the Stealth neuronavigational system (Medtronic, Minneapolis, MN, USA);
the location and spatial coordinates of tissue sampling sites were recorded to align with HDI
results. Each subject had at least one recorded tissue sampling site. Twelve tumor samples were
prepared for this study. The entire HDI analysis was performed blinded to all other data (i.e.,
clinical data and information about patient surgeries and outcomes).
MRI data acquisition
MRI scans were performed on a 3-Tesla positron emission tomography (PET)/MRI system,
the Siemens Biograph mMR (Siemens Health Care, Erlangen, Germany). MR images were
acquired via the Comprehensive Neuro-Oncology Data Repository (CONDR) imaging proto-
col used for brain tumors [21]. The protocol included pre-gadolinium and post-gadolinium
T1-weighted (T1W) imaging (TR = 18 ms, TE = 4.38 ms, in-plane resolution = 1.0 × 1.0 mm2,
Table 1. Characteristics of patients and tumor grades detected by biopsy.
Patient No. Age Range (years) Tumor Pathology Tumor Grade IDH Mutant
S1 40s Oligodendroglioma WHO III Yes
S3 60s Oligodendroglioma WHO II Yes
S4 30s Oligodendroglioma WHO II Yes
S6 30s Anaplastic astrocytoma WHO III Yes
S7 30s Astrocytoma WHO II Yes
S8 30s Oligodendroglioma WHO II Yes
S9 40s Oligodendroglioma WHO III Yes
IDH, Isocitrate dehydrogenase; WHO, World Health Organization.
https://doi.org/10.1371/journal.pone.0225093.t001
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slice thickness = 1.0 mm); magnetization-prepared rapidly acquired gradient echo (TR = 2300
ms, TE = 2.95 ms, TI = 900 ms, in-plane resolution = 1.0 × 1.0 mm2, slice thickness = 1.0 mm);
dynamic susceptibility contrast (DSC) perfusion-weighted imaging (TR = 1930 ms, TE = 36
ms, in-plane resolution = 2.2 × 2.2 mm2, slice thickness = 5.0 mm); T2-weighted (T2W) fluid-
attenuated inversion recovery (FLAIR) (TR = 8500 ms, TE = 133 ms, flip angle = 130 degrees,
in-plane resolution = 0.9 × 0.9 mm2, slice thickness = 5.0 mm); and standard diffusion tensor
imaging (DTI) (TR = 9000 ms, TE = 91 ms, in-plane resolution = 2.2 × 2.2 mm2, slice thick-
ness = 3.0 mm). Clinical DTI scans were acquired using a 12-direction gradient scheme with a
maximum b value of 1000 s/mm2.
We also designed and incorporated a diffusion scheme for HDI data acquisition that was
used in addition to the clinical DTI scan. The new diffusion protocol included 74 diffusion
directions distributed uniformly in the three-dimensional space, with 74 different b values; it
was administered across four separate sessions to improve patient tolerance. Each diffusion
gradient had a unique b value, and all of the b values were uniformly distributed between 0
and 2000 s/mm2. The maximum b value for each session was 2000 s/mm2. The imaging
parameters were as follows: TR = 9500 ms; TE = 93 ms; in-plane resolution = 2.0 × 2.0 mm2;
and slice thickness = 2.0 mm.
MRI image processing
MRI preprocessing. For each individual subject, all MRI sequences were coregistered to a
target post-contrast T1W image using the Multimodal Glioma Analysis (MGA) pipeline [22].
Each subject’s T1W image was registered to a T1W atlas template image, and other T1W and
T2W sequences were coregistered with the subject’s T1W target image. T1W! T1W registra-
tion used the maximization of spatial correlation [23], whereas cross-modal registration (e.g.,
T2W! T1W) used the alignment of intensity gradients [24]. Perfusion and diffusion parame-
ter maps were transformed to the T1W target space using a transformation matrix obtained
from coregistering respective sequences. The coregistration quality was verified using built-in
MGA quality control metrics.
Diffusion and perfusion processing. After the acquisition and registration steps were
completed, each subject’s raw diffusion and perfusion data were processed. The MGA pipeline
was used for diffusion and perfusion processing. MGA precedes perfusion modeling by cor-
recting signal intensity across slices and registering all frames to a middle time frame. Perfu-
sion modeling is initialized by the automatic estimation of a local arterial input function and
the selection of a convolution/deconvolution method. The arterial input function is defined
using the Bayesian tissue model [25]. Diffusion data were processed based on the standard
DTI model [26]. With the use of these methods, MGA computed the cerebral blood volume
(CBV), mean transit time, and cerebral blood flow maps for the DSC scans. For diffusion-
weighted scans, the ADC was computed.
HDI processing. Diffusion data acquired with the use of our new diffusion protocol were
analyzed using the HDI method. HDI was developed based on the multiple tensor formula-
tions used in the DBSI model [16, 17]. Briefly, HDI modeled the diffusion-weighted signal
from each imaging voxel using a combination of anisotropic and isotropic tensor components,
as described by Eq (1). Each of the tensor components is described as a standard diffusion ten-
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In Eq (1), |bk| is the b value of the kth diffusion gradient (k = 1, 2, . . ., K). Sk is the measured
diffusion-weighted signal that corresponds with the kth diffusion gradient. HDI anisotropic
components (i.e., the first term on the right side of Eq (1)) were used to model the complex
neuronal structures invaded by tumor. NAniso is the number of anisotropic tensors in the imag-
ing voxel; ψik is the angle between the kth diffusion gradient and the principal direction of the
ith anisotropic tensor; λ||_i and λ⏊_i are the axial and radial diffusivities, respectively, of the ith
anisotropic tensor; and fi is the signal intensity fraction for the ith anisotropic tensor. The HDI
isotropic spectrum (i.e., the second term on the right side of Eq (1)) was divided into several
nonoverlapping windows on the basis of previously published reports of ADC ranges for dif-
ferent tumor stages [8, 9], and a and b are the low (0 μm2/ms) and high (40 μm2/ms) diffusivity
limits, respectively, for the isotropic diffusion spectrum f(D). The number of anisotropic and
isotropic diffusion components and the signal intensity fractions that correspond with all dif-
fusion components are the key parameters to be solved. The unavoidable measurement and
modeling noise will make the direct solution of Eq (1) unstable due to its ill-posed nature [16,
17]. A regularization technique that incorporated the non-negativity of the solution was
employed previously in DBSI to stabilize the solution [16, 17], and the same regularization
technique was employed in this work. Specifically, isotropic diffusion components with diffu-
sivity between 0 and 0.3 μm2/ms were associated with cellularities [16, 17], and those that ran-
ged between 0.3 and 0.8 μm2/ms were associated with the slow extracellular diffusion of water
trapped between tumor cells, thereby reflecting the packing density of the tumor cells. The iso-
tropic diffusion components with diffusivity that ranged between 0.8 and 2.5 μm2/ms were
associated with fast extracellular water diffusion, thereby reflecting edema. HDI also acquired
diffusion-weighted images with small b values to capture the ultrafast isotropic diffusion
between 5 and 40 μm2/ms. This ultrafast diffusion has been previously described as the intra-
voxel incoherent motion (IVIM) effect and associated with capillary blood perfusion [28].
Within each imaging voxel for each tumor, the following HDI-derived metrics were quanti-
fied: cellularity fraction (CF), slow hindered diffusion fraction (sHF), fast hindered diffusion
Fig 1. Schematic figure of the isotropic spectrum signals from Heterogeneity Diffusion Imaging. Isotropic diffusivity is used to
define each pathological component within a brain tumor. The isotropic diffusivity cutoffs for each of the pathological components
were selected from previous diffusion magnetic resonance imaging studies of brain tumors. Specifically, the isotropic diffusion
components with diffusivity that ranged between 0.3 and 0.8 μm2/ms were associated with the dense packing of tumor cells. The
components with diffusivity that ranged between 0.8 and 2.5 μm2/ms were associated with extracellular water edema. The
components with diffusivity that ranged between 5 and 40 μm2/ms were associated with capillary blood perfusion within tumors.
https://doi.org/10.1371/journal.pone.0225093.g001
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fraction (fHF), and perfusion fraction (PF). The detailed partition of the isotropic spectrum by
HDI is shown in Fig 1.
Surgical treatment
After the MRI, patients underwent stereotactic biopsy followed by partial or complete resec-
tion. For each patient, at least one tumor sample was obtained with a stereotactic screen cap-
ture taken with the Stealth station. The neuronavigation-guided T1W images of the biopsy
tissue-sampling sites were shown on axial, coronal, and sagittal views (Fig 2). T1W contrast-
enhanced, T2W, and FLAIR images were co-registered by MGA and loaded into the 3D Slicer
software platform (http://www.slicer.org) [29] to produce 5-mm diameter spheres that were
centered at each surgical tumor sampling site.
Regions of interest and statistical analysis
Volumetric tumor regions of interest (ROIs) were drawn manually from the FLAIR images.
All manual regions of interest (mROIs) were approved by a board-certified neuroradiologist
(G.G.). HDI model analysis was performed on the selected mROIs. The ROIs at the tissue sam-
pling sites (tsROIs) were also colocalized on HDI images to quantify the HDI findings. A two-
sample t-test was performed to compare ADC, CBV, and HDI metrics between the World
Health Organization (WHO) II and III tumor groups at tsROIs. The average HDI-derived PF
was correlated with the DSC perfusion MRI-derived CBV index. The Pearson correlation coef-
ficient was used to evaluate the association between CBV- and HDI-derived metrics. P values
of less than .05 were considered significant. Statistical analysis was performed using SAS 9.4
software (SAS Institute Inc., Cary, NC, USA).
Fig 2. Neuronavigation-guided anatomic images of biopsy tissue sampling sites. Neuronavigation-guided
T1-weighted images of the biopsy tissue sampling site at (A) axial, (B) coronal, and (C) sagittal views. (D) The tissue
sampling site is labeled on the T2-weighted fluid attentuation inversion recovery image. Purple arrows indicate the
passive biopsy needle.
https://doi.org/10.1371/journal.pone.0225093.g002
Evaluation of gliomas with Heterogeneity Diffusion Imaging
PLOS ONE | https://doi.org/10.1371/journal.pone.0225093 November 14, 2019 6 / 15
Results
In all patients, HDI metrics demonstrated heterogeneous spatial distributions within tumors.
Fig 3 shows a representative case from the low-grade tumor group for a woman in her 70s
who had been diagnosed with WHO grade II oligodendroglioma. The subject underwent stan-
dard-of-care imaging and HDI scanning. The T1W post-contrast MRI demonstrated
decreased signal intensity in the tumor region (Fig 3A). Elevated FLAIR signal intensity (Fig
3B) and increased ADC (Fig 3C) were also found in the tumor region. Elevated cellularity frac-
tion was found in the HDI-CF map, and the cellularity distribution was heterogeneous within
the tumor (Fig 3E). No increased hindered diffusion fraction was identified in the HDI-sHF
map (Fig 3F). An elevated hindered diffusion fraction was found in the HDI-fHF map (Fig
3G). A lack of elevated perfusion based on the CBV (Fig 3D) and HDI-PF (Fig 3H) maps was
observed in this patient.
Another representative case for the high-grade tumor group is shown in Fig 4 for a man in
his 50s who was diagnosed with WHO grade III oligodendroglioma. Representative MRI
images of this patient are shown in the figure. T1W post-contrast MRI demonstrated decreased
signal intensity in the tumor (Fig 4A). Elevated signal intensity (Fig 4B) and increased ADC
(Fig 4C) were also found in the tumor. Elevated cellularity fraction was found in the HDI-CF
map, and the cellularity distribution was heterogeneous within the tumor (Fig 4E). Elevated
sHF (Fig 4F) and fHF (Fig 4G) were observed in this patient. Elevated perfusion based on the
CBV (Fig 4D) and HDI-PF (Fig 4H) maps was found in the high-grade brain tumor lesion.
Fig 3. Imaging from a woman in her 70s diagnosed with World Health Organization grade II recurrent
oligodendroglioma. (A) The T1-weighted post-contrast image shows a lesion with decreased signal intensity. (B) The
fluid-attenuated inversion recovery image and (C) the diffusion magnetic resonance imaging-derived apparent
diffusion coefficient show a lesion with an increased signal. (D) The dynamic susceptibility contrast-derived cerebral
blood volume map and the Heterogeneity Diffusion Imaging-derived (E) cellularity fraction, (F) slow hindered
diffusion fraction, (G) fast hindered diffusion fraction, and (H) perfusion fraction maps were generated on manually
defined tumor regions and overlaid on the fluid-attenuated inversion recovery image. No elevated cerebral blood
volume and Heterogeneity Diffusion Imaging-derived slow hindered diffusion fraction and perfusion fraction are
shown in the tumor region. The elevated Heterogeneity Diffusion Imaging-derived cellularity fraction and fast
hindered diffusion fraction are shown in the tumor region.
https://doi.org/10.1371/journal.pone.0225093.g003
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Fig 4. Imaging from a man in his 50s diagnosed with World Health Organization grade III oligodendroglioma.
(A) The T1-weighted post-contrast image shows a lesion with decreased signal intensity. (B) The fluid-attenuated
inversion recovery image and (C) the diffusion magnetic resonance imaging-derived apparent diffusion coefficient
show a lesion with an increased signal. (D) The dynamic susceptibility contrast-derived cerebral blood volume map
and the Heterogeneity Diffusion Imaging-derived (E) cellularity fraction, (F) slow hindered diffusion fraction, (G) fast
hindered diffusion fraction, and (H) perfusion fraction maps were generated on manually defined tumor regions of
interest and overlaid on the fluid-attenuated inversion recovery image. The elevated cerebral blood volume and
Heterogeneity Diffusion Imaging-derived cellularity fraction, slow hindered diffusion fraction, fast hindered diffusion
fraction, and perfusion fraction are shown in the tumor region.
https://doi.org/10.1371/journal.pone.0225093.g004
Fig 5. Boxplots of imaging metrics. There is no group significant difference in (A) apparent diffusion coefficient or
(B) Heterogeneity Diffusion Imaging (HDI)-derived cellularity fraction between the World Health Organization
(WHO) II and III groups. (C) The HDI-derived slow hindered diffusion fraction is significantly higher in the WHO III
group as compared with the WHO II group. (D) There is no group significant difference in HDI-derived fast hindered
diffusion fraction between the WHO II and III groups. (E) The cerebral blood volume is significantly higher in the
WHO III group as compared with the WHO II group. (F) The HDI-derived perfusion fraction is significantly higher
in the WHO III group as compared with the WHO II group. Boxes indicate 25th to 75th percentiles, and thin lines
indicate 5th and 95th percentiles. �, P< .05.
https://doi.org/10.1371/journal.pone.0225093.g005
Evaluation of gliomas with Heterogeneity Diffusion Imaging
PLOS ONE | https://doi.org/10.1371/journal.pone.0225093 November 14, 2019 8 / 15
Imaging metrics including ADC, CBV, and HDI-derived indices were compared between
the WHO II and III groups at the tissue sampling sites, and details are shown in Fig 5. No
group significant difference was found in ADC between the WHO II and III groups (Fig 5A).
The increasing trend of HDI-derived CF was observed in the WHO III group (Fig 5B). The
HDI-derived sHF was significantly elevated in the WHO III group as compared with the
WHO II group (Fig 5C). HDI-fHF was not significantly different between the WHO II and III
groups (Fig 5D). The CBV generated from DSC perfusion imaging was statistically signifi-
cantly higher in the WHO III group as compared with the WHO II group (Fig 5E). Similar to
the CBV metrics, the HDI-derived perfusion index (PF) was statistically significantly higher in
the WHO III group as compared with the WHO II group (Fig 5F).
The correlation coefficients between the DSC perfusion imaging and HDI metrics were
evaluated, as shown in Fig 6. A statistically significant positive correlation was seen between
CBV and HDI-derived PF (Pearson’s r = 0.77, P = .003) (Fig 6A). A significant positive correla-
tion between CBV and HDI-sHF (Fig 6B) was also noted (Pearson’s r = 0.83, P< .001). CBV
was not correlated with HDI-CF or HDI-fHF (Fig 6C and 6D).
Discussion
Tumor heterogeneity is ubiquitous, especially in malignant tumors [30], which can contain
different grades of tumor cells, edema, and vascular structures within each imaging voxel and
across the entire tumor. The complexity of the tumor microstructure imposes serious chal-
lenges for diagnosis, treatment planning, and post-treatment evaluation. HDI was developed
as a novel diffusion MRI technique to characterize tumor heterogeneity by separating and
quantifying multiple pathological components.
Although conventional diffusion-weighted imaging (DWI) and DTI have been employed to
characterize tumors and to evaluate treatment response in patients with primary brain tumors
Fig 6. The associations between dynamic susceptibility contrast-derived cerebral blood volume and Heterogeneity
Diffusion Imaging-derived indices. Scatter plots showing the significant correlations between (A) dynamic
susceptibility contrast perfusion imaging-generated cerebral blood volume (CBV) and Heterogeneity Diffusion
Imaging (HDI)-derived perfusion fraction and (B) CBV and HDI-derived slow hindered diffusion fraction in all
subjects at the tissue sampling regions. No significant correlations were found between (C) CBV and HDI-derived
cellularity fraction or (D) CBV and HDI-derived fast hindered diffusion fraction.
https://doi.org/10.1371/journal.pone.0225093.g006
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[9, 12], these methods are not capable of detecting multiple tumor pathologies due to their sin-
gle diffusion tensor assumption. ADC measures from DWI have been widely used in diagnos-
tic oncology, and the reduced ADC of some tumors has been associated with a high density of
tumor cells [9]. However, the sensitivity and specificity of ADC for detecting malignant
tumors may be decreased by the edema and/or tumor necrosis that coexists in the lesions [31].
The development of advanced models and model-free diffusion MRI techniques has dem-
onstrated improvements in tumor detection and characterization. For example, by making no
assumptions about tissue composition, diffusion kurtosis imaging provides a model-free way
to quantify non-Gaussian water diffusion [32]. This type of imaging has demonstrated its sen-
sitivity for grading tumors [33] as well as its high diagnostic accuracy for separating low- from
high-grade gliomas through meta-analysis [34]. Similarly, the stretched exponential method—
developed to describe diffusion-related signal decay as a continuous distribution, with no
assumptions made about the number of participating sources [35]—has demonstrated better
performance for differentiating tumor grades as compared with ADC and DTI [36]. Although
both the diffusion kurtosis imaging and stretched exponential methods show that non-Gauss-
ian diffusion effects can be used as general heterogeneity biomarkers, it is unknown whether
the non-Gaussian diffusion effects are mainly contributed by tumor cells or by the neuronal
structures invaded by the tumor. Generalized q-sampling imaging derives complex intravoxel
and intervoxel fiber alignment in tissue [37]. A rodent and human glioblastoma study has indi-
cated that q-sampling imaging detected unique intratumor structural features that correlate
with both intratumor biological heterogeneity and overall survival [38]. However, no isotropic
diffusion components directly associated with tumor cells were included in the present study.
Restriction spectrum imaging is an advanced DWI modeling technique that allows for the
more direct measurement of tumor cells due to its ability to distinguish among different pools
of water within tumor tissues [39]. Previous studies have demonstrated that the restriction
spectrum imaging index has increased sensitivity and specificity as compared with ADC for
the assessment of brain tumors [39]. Model-based advanced diffusion methods have the
advantage of providing more specific subvoxel information. HDI was developed on the basis
of the data-driven multicompartment model DBSI [16–20], with the extension of the full iso-
tropic diffusion spectrum to 40 μm2/ms. This pilot study demonstrated that HDI is capable of
imaging and quantifying multiple tumor pathological components and microvascularity per-
fusion simultaneously within brain tumors in a single clinical diffusion scan, which distin-
guishes it from previous models.
In this study, HDI employed CF and sHF images to characterize the spatial distributions of
tumor cellularity and its packing density, which cannot be revealed from conventional ADC
maps and other advanced diffusion methods. The representative images from one low-grade
tumor patient with WHO II oligodendroglioma (see Fig 3) and one high-grade tumor patient
with WHO III oligodendroglioma (see Fig 4) showed very heterogeneous tumor cellularity dis-
tributions. The conventional ADC measurements were incapable of differentiating between
patients with WHO II and III tumors (see Fig 5A), thereby demonstrating ADC’s limited capa-
bility for characterizing heterogeneous tumor microenvironments. HDI-CF showed an
increased trend in the WHO III group as compared with the WHO II group, but no statisti-
cally significant difference was found (see Fig 5B), probably due to the small sample size. Inter-
estingly, HDI demonstrated that the WHO III group had a much higher HDI-sHF than that
found in the WHO II group (see Fig 5C), which suggests that there are more densely packed
tumor cells in the WHO III group as compared with the WHO II group. The HDI-fHF find-
ings (see Fig 5D) demonstrated that the extracellular water fractions are comparable between
the two groups. These findings suggest that HDI parameters can better quantify the micro-
structural heterogeneity within tumors and that these parameters may provide higher
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sensitivity for categorizing tumors as compared with conventional ADC. In this pilot study, we
demonstrated the feasibility of using HDI to analyze heterogeneous brain tumors. No auto-
matic method was used to classify the tumor grades based on the HDI findings due to the
small sample size. A larger study will enable us to better define the relationship between tumor
grade and HDI distribution, which will allow for an automatic tumor grade evaluation.
The discovery of gadolinium tissue deposition [40] and the uncertainty surrounding its
effects compel the imaging community to find alternative methods for quantifying perfusion.
The conventional IVIM method [28] employs a simple biexponential model to quantify perfu-
sion (fast diffusion) and diffusion (slow diffusion) effects in biological tissue. Although con-
ventional IVIM-derived perfusion metrics have improved the diagnostic performance of
arterial spin labeling-derived cerebral blood flow and have a strong correlation with cerebral
blood flow [41], their accuracy and reliability have not been well accepted, at least partially due
to the associated overly simplified biexponential computation model for complex biological
tissues. To address this limitation of conventional IVIM, HDI incorporates the “ultrafast”
IVIM component associated with capillary blood perfusion [41] into the comprehensive
modeling of neuronal components, tumor cellularity, and extracellular water (Eq (1)). In this
study, the HDI perfusion component was compared with clinical DSC perfusion imaging in all
subjects. The strong correlation between HDI-derived perfusion and DSC-derived CBV (Fig
6A) and the similar spatial distribution patterns between those measures (see Fig 3D and 3H
and Fig 4D and 4H) suggest that the HDI-derived perfusion index holds great promise as a
complementary noninvasive method for accurately quantifying tumor CBV for patients who
cannot receive contrast material for clinical DSC scans. The findings that CBV correlated with
HDI-sHF (see Fig 6B) suggest that blood perfusion increases with an increased packing density
of tumor cells.
The results of the biopsy evaluation of tumors highly depends on the location of the tissue
sampling. The suboptimal selection of the biopsy site may lead to underdiagnosis, undertreat-
ment, and higher tumor recurrence rates. Conventional T1W or T2W imaging has been previ-
ously employed for MRI-guided biopsy [42], and DWI has also been used to optimize biopsy
target selection [43]. However, those imaging contrasts may not distinguish tumors from
other pathologies such as regions with edema or tumor necrosis. This study has demonstrated
that HDI could be a promising noninvasive tool for the guidance of biopsy, surgery, and
radiotherapy.
Each biopsy site represents a different region of tumor that is localized by the Stealth neuro-
navigational system and superimposed on both anatomical maps and maps of HDI-derived
indices. Spatial heterogeneity is a fundamental feature of brain tumors [44]. Different sampling
regions within one tumor usually have different characterizations, which is evidenced by the
diffusion and perfusion data from the same subject (see Fig 4). Thus, including multiple sam-
ples from the same subject will increase statistical power without biasing the analysis.
There are several limitations of this pilot study. First, the sample size is small. Future studies
with larger numbers of patients will be needed to further validate the HDI technique. Second,
the isotropic diffusivity thresholds were selected based on results from previously published
DBSI studies. More patient data and histology studies are needed to further refine and opti-
mize the threshold selection. Third, the fixed diffusion time employed in this study could lead
to potential overlapping among different isotropic components. Incorporating multiple diffu-
sion time measurement [45] could potentially improve HDI’s accuracy when characterizing
the tumor microenvironment.
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Conclusions
HDI was developed in this pilot study to noninvasively characterize brain tumor heterogene-
ity. The preliminary data demonstrate the capability of HDI to quantify the microenvironment
heterogeneity of brain tumors, including tumor cell fraction, packing density, edema, and cap-
illary blood perfusion in a single diffusion MRI examination. The HDI results are consistent
with pathology assessments of biopsy tissues and DSC measurements of blood perfusion.
Larger studies will be needed to further validate HDI and to establish its role in the clinical
management of patients with brain tumors.
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